Insmed (INSM)
NASDAQ:INSM
INSM Stock Chart & Stats
$146.74
-$1.02(-1.54%)
At close: 4:00 PM EST
$146.74
-$1.02(-1.54%)
Day’s Range― - ―
52-Week Range$63.81 - $212.75
Previous CloseN/A
Volume462.72K
Average Volume (3M)2.31M
Market Cap
$31.67B
Enterprise Value$31.89B
Total Cash (Recent Filing)$1.43B
Total Debt (Recent Filing)$768.16M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Apr 30, 2026EPS Estimate
-0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.54
Shares Outstanding215,551,900
10 Day Avg. Volume2,036,732
30 Day Avg. Volume2,308,700
Financial Highlights & Ratios
PEG Ratio-1.93
Price to Book (P/B)50.31
Price to Sales (P/S)61.31
P/FCF Ratio-38.43
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue52.58
Enterprise Value/Gross Profit66.22
Enterprise Value/Ebitda-27.11
Forecast
1Y Price Target
$215.67Price Target Upside46.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)-2.59
Revenue Forecast (FY)$1.71B
Bulls Say, Bears Say
Bulls Say
Commercial Launch AdoptionProprietary pulmonologist survey and management reports showing rising prescriptions, low treatment discontinuation, and improving refill rates indicate the Brinsupri launch is moving from single prescriptions toward repeat use, supporting stronger commercial momentum.
Pipeline ExpansionAcquisition of INS1148 and plans to develop fully owned next-generation DPP1 inhibitors and antibody candidates broaden the pipeline into interstitial lung disease and severe asthma, creating additional potential growth drivers beyond bronchiectasis.
Safety ProfileFavorable CEDAR safety findings, with no new safety signals even at higher doses, may bolster physician confidence in brensocatib and reduce adoption barriers tied to tolerability concerns.
Bears Say
Clinical Trial FailureCEDAR trial failure in hidradenitis suppurativa and discontinuation of that program remove a potential label extension for brensocatib and weaken near-term clinical upside.
Indication Breadth RiskDiscontinuation of the chronic rhinosinusitis and hidradenitis suppurativa programs raises doubts about how broadly brensocatib can be applied across inflammatory diseases, increasing reliance on bronchiectasis for long-term growth.
Revenue VariabilityInsurance reverification, inventory dynamics, and deductible resets could lead to uneven Brinsupri revenue patterns, reducing near-term sales visibility and introducing downside risk to the stock.
Insmed News
INSM FAQ
What was Insmed’s price range in the past 12 months?
Insmed lowest stock price was $63.81 and its highest was $212.75 in the past 12 months.
What is Insmed’s market cap?
Insmed’s market cap is $31.67B.
When is Insmed’s upcoming earnings report date?
Insmed’s upcoming earnings report date is Apr 30, 2026 which is in 14 days.
How were Insmed’s earnings last quarter?
Insmed released its earnings results on Feb 19, 2026. The company reported -$1.54 earnings per share for the quarter, missing the consensus estimate of -$1.071 by -$0.469.
Is Insmed overvalued?
According to Wall Street analysts Insmed’s price is currently Undervalued.
Does Insmed pay dividends?
Insmed does not currently pay dividends.
What is Insmed’s EPS estimate?
Insmed’s EPS estimate is -0.96.
How many shares outstanding does Insmed have?
Insmed has 215,551,900 shares outstanding.
What happened to Insmed’s price movement after its last earnings report?
Insmed reported an EPS of -$1.54 in its last earnings report, missing expectations of -$1.071. Following the earnings report the stock price went up 6.545%.
Which hedge fund is a major shareholder of Insmed?
Currently, no hedge funds are holding shares in INSM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insmed Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$215.67 (46.97% Upside)
$215.67 (46.97% Upside)
Blogger Sentiment
Bullish
INSM Sentiment 85%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $810.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 8.7%
Last 30 Days ▲ 8.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
115.96%
12-Months-Change
Fundamentals
Return on Equity
-168.36%
Trailing 12-Months
Asset Growth
11.82%
Trailing 12-Months
Company Description
Insmed
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
INSM Company Deck
INSM Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a strongly positive commercial momentum driven by Brinsupri's launch (first full-quarter net revenue of $144.6M and guidance of at least $1B in 2026), solid ARIKAYCE growth (Japan +40% YoY) and a strong balance sheet (~$1.4B cash). Clinical progress (TPIP orphan designation and planned Phase III) and pipeline expansion via acquisitions were additional positives. Near-term challenges noted include early-stage depth of prescribing, some payer documentation requirements and increased operating spend (including ~$70M of one-time Q4 cash items). Management believes these lowlights are manageable and reiterated a path to cash flow positivity while retaining flexibility for selective business development. On balance, the highlights materially outweigh the lowlights.View all INSM earnings summariesINSM Stock 12 Month Forecast
Average Price Target
$215.67
▲(46.97% Upside)
Technical Analysis
Ownership Overview
0.76% Insiders
30.18% Mutual Funds
0.20% Other Institutional Investors
49.93% Public Companies and Individual Investors